An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status

This prospective open-label pilot study evaluated the effectiveness and safety of adalimumab and the relationship to antibodies against infliximab (IFX) in adult patients with active rheumatoid arthritis (RA) who had been treated previously with IFX and experienced treatment failure owing to lack or...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Bijl, Arie E., Breedveld, Ferdinand C., Antoni, Christian E., Kalden, Joachim R., Kary, Sonja, Burmester, Gerd R., Beckmann, Christina, Unnebrink, Kristina, Kupper, Hartmut
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2008
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2468311/
https://www.ncbi.nlm.nih.gov/pubmed/18350329
http://dx.doi.org/10.1007/s10067-008-0866-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2468311/
https://www.ncbi.nlm.nih.gov/pubmed/18350329
http://dx.doi.org/10.1007/s10067-008-0866-4

Ejemplares similares